drugset / Trial / NCT03496207

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (PAH)

NCT03496207

Phase 2 Completed 106 enrolled Acceleron Pharma, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study A011-09 is designed to assesses the efficacy and safety of sotatercept (ACE-011) relative to placebo in adults with pulmonary arterial hypertension (PAH). Eligible participants will receive study treatment for 24 weeks during the placebo-controlled treatment period, and then will be eligible to enroll into a 30-month extension period during which all participants will receive sotatercept. All treated patients will also undergo a follow-up period after last study drug treatment.

Timeline

Start
2018-06-13
Primary completion
2022-03-09
Completion
2022-03-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sotatercept Protein / enzyme biologic 0.3 mg/kg Subcutaneous
Subject Sotatercept Protein / enzyme biologic 0.7 mg/kg Subcutaneous